Efficacy and safety of capecitabine and temozolomide (CAPTEM) in advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN) – A systematic review and metanalysis

#3864

Introduction: Gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN) are heterogeneous tumors, with multiple therapeutic options for advanced stages. The combination of capecitabine and temozolomide (CAPTEM) is increasingly used for advanced GEP-NEN, but evidence on results is sparse.

Aim(s): We conducted a systematic review and meta-analysis to assess the efficacy and safety of CAPTEM in advanced GEP-NEN.

Materials and methods: We included studies enrolling patients with any grade GEP-NENs undergoing CAPTEM. A meta-analysis with random effects model, progression-free survival (PFS) as primary endpoint, and severe adverse events (SAEs) rate as secondary endpoint was performed. Different treatment schedules were considered. The heterogeneity (I2) was interpreted by meta-regression analysis considering the following covariates: Study type and design, sample size, metastatic disease rate, rate of primary pancreatic NENs, previous treatments, and study quality.

Conference:

Presenting Author: Tacelli M

Authors: Tacelli M, Massironi S, Gallo C, Bina N, Stornello C,

Keywords: chemotherapy, pfs, progression-free survival, adverse events,